Ze Cong1, Oth Tran2, James Nelson3, Monica Silver3, Karen Chung4. 1. GRAIL, LLC, a subsidiary of Illumina, Inc., Menlo Park, CA, USA. zcong@grailbio.com. 2. Previously IBM Watson Health, San Francisco, USA. 3. IBM Watson Health, Cambridge, MA, USA. 4. GRAIL, LLC, a subsidiary of Illumina, Inc., Menlo Park, CA, USA.
Abstract
BACKGROUND: The total economic burden of cancer reflects direct and indirect costs, including productivity loss due to employment change, absenteeism, and presenteeism of patients and caregivers. OBJECTIVE: This study estimated the magnitude of employment decrease, work absence (WA), short-term disability (STD), long-term disability (LTD), and associated indirect costs among employees newly diagnosed with metastatic versus non-metastatic cancer in the USA. METHODS: IBM® MarketScan® Commercial Claims and Encounters and Health and Productivity Management databases were used to identify employees aged 18-64 years and newly diagnosed with any cancer from 2009 to 2019. Proportions of patients with employment decrease, WA, STD, and LTD claims, and number of days missing from work were summarized by metastatic status during the first 12 months after diagnosis and the entire follow-up period. Subgroup analyses were conducted by age (< 50 years, ≥ 50 years) and cancer type (breast, lung, colon, pancreatic, and liver cancer). RESULTS: During the first year after diagnosis, compared to patients without metastases, significantly higher proportions of patients with metastases had employment decrease and STD or LTD claims (p < 0.001). The mean total number of days missing from work for patients with versus without metastases was 33.39 versus 14.91 (ratio = 2.40), 64.05 versus 27.15 (ratio = 2.36), and 105.93 versus 46.29 (ratio = 2.29) days within 3, 6, and 12 months after diagnosis, respectively. Estimates of indirect cost differences between the two groups ranged from $6,877 to $22,283 in the first year. CONCLUSION: Earlier detection of cancer may reduce productivity loss of patients and indirect costs by initiating treatment before cancer progresses to late stage.
BACKGROUND: The total economic burden of cancer reflects direct and indirect costs, including productivity loss due to employment change, absenteeism, and presenteeism of patients and caregivers. OBJECTIVE: This study estimated the magnitude of employment decrease, work absence (WA), short-term disability (STD), long-term disability (LTD), and associated indirect costs among employees newly diagnosed with metastatic versus non-metastatic cancer in the USA. METHODS: IBM® MarketScan® Commercial Claims and Encounters and Health and Productivity Management databases were used to identify employees aged 18-64 years and newly diagnosed with any cancer from 2009 to 2019. Proportions of patients with employment decrease, WA, STD, and LTD claims, and number of days missing from work were summarized by metastatic status during the first 12 months after diagnosis and the entire follow-up period. Subgroup analyses were conducted by age (< 50 years, ≥ 50 years) and cancer type (breast, lung, colon, pancreatic, and liver cancer). RESULTS: During the first year after diagnosis, compared to patients without metastases, significantly higher proportions of patients with metastases had employment decrease and STD or LTD claims (p < 0.001). The mean total number of days missing from work for patients with versus without metastases was 33.39 versus 14.91 (ratio = 2.40), 64.05 versus 27.15 (ratio = 2.36), and 105.93 versus 46.29 (ratio = 2.29) days within 3, 6, and 12 months after diagnosis, respectively. Estimates of indirect cost differences between the two groups ranged from $6,877 to $22,283 in the first year. CONCLUSION: Earlier detection of cancer may reduce productivity loss of patients and indirect costs by initiating treatment before cancer progresses to late stage.
Authors: Sean Nicholson; Mark V Pauly; Daniel Polsky; Catherine M Baase; Gary M Billotti; Ronald J Ozminkowski; Marc L Berger; Claire E Sharda Journal: Appl Health Econ Health Policy Date: 2005 Impact factor: 2.561
Authors: Stella Chang; Stacey R Long; Lucie Kutikova; Lee Bowman; Denise Finley; William H Crown; Charles L Bennett Journal: J Clin Oncol Date: 2004-09-01 Impact factor: 44.544
Authors: A J Tevaarwerk; J W Lee; M E Sesto; K A Buhr; C S Cleeland; J Manola; L I Wagner; V T S Chang; M J Fisch Journal: J Cancer Surviv Date: 2013-02-02 Impact factor: 4.442
Authors: Janet S de Moor; Emily C Dowling; Donatus U Ekwueme; Gery P Guy; Juan Rodriguez; Katherine S Virgo; Xuesong Han; Erin E Kent; Chunyu Li; Kristen Litzelman; Timothy S McNeel; Benmei Liu; K Robin Yabroff Journal: J Cancer Surviv Date: 2016-07-16 Impact factor: 4.442
Authors: K Robin Yabroff; Cathy J Bradley; Angela B Mariotto; Martin L Brown; Eric J Feuer Journal: J Natl Cancer Inst Date: 2008-12-09 Impact factor: 13.506
Authors: Khalid M Kamal; Jordan R Covvey; Ankur Dashputre; Somraj Ghosh; Surbhi Shah; Monali Bhosle; Christopher Zacker Journal: J Manag Care Spec Pharm Date: 2017-02